Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, TREND1, Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 4/24/2018 10:56:15 PM - Followers: 398 - Board type: Free - Posts Today: 0


Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.        

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering 04/09/2018 04:10:00 PM
MNKD News: Statement of Ownership (sc 13g) 04/09/2018 11:41:24 AM
MNKD News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 04/06/2018 04:12:41 PM
MNKD News: Current Report Filing (8-k) 04/06/2018 04:08:42 PM
MNKD News: MannKind Announces $28.0 Million Registered Direct Offering 04/06/2018 01:58:59 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#27951  Sticky Note $MNKD Could MannKind Corporation Be a Millionaire-Maker $Pistol Pete$ 04/02/18 01:50:36 PM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#28159   It started from MAR 29 so I think $Pistol Pete$ 04/24/18 10:56:15 PM
#28158   Yeah they are possibly f'ed Sugarplum 04/24/18 10:24:09 PM
#28157   They have 24-25 days to cover and I $Pistol Pete$ 04/24/18 09:58:42 PM
#28156   36MM short 30% Sugarplum 04/24/18 08:16:36 PM
#28155   No, it will have no effect on either parkourstar 04/24/18 07:44:11 PM
#28154   You are right, the label does not change. SidVicious 04/24/18 07:38:25 PM
#28153   No, it is not good news. ALL parkourstar 04/24/18 07:31:49 PM
#28152   This news isn't as ground breaking as I SidVicious 04/24/18 07:11:52 PM
#28151   Better cover shortie...imo TTIME 04/24/18 06:52:06 PM
#28150   And you could be 100% right. It is SidVicious 04/24/18 06:51:38 PM
#28149   Beware that you may be WAY wrong: parkourstar 04/24/18 06:44:20 PM
#28148   Yes Sir and this will bring a huge $Pistol Pete$ 04/24/18 06:27:40 PM
#28147   VERY BIG news. If all REMS is no SidVicious 04/24/18 06:21:31 PM
#28146   $MNKD I really love the major news after $Pistol Pete$ 04/24/18 06:19:55 PM
#28145   That’s very good buy. My average is $1.85 $Pistol Pete$ 04/24/18 06:14:05 PM
#28144   Let’s cross our fingers. I bought 300,000 below $Pistol Pete$ 04/24/18 06:12:52 PM
#28143   Bought a lot in below 2 back prior SidVicious 04/24/18 06:11:50 PM
#28142   That’s a nice buy from u. This is $Pistol Pete$ 04/24/18 06:06:35 PM
#28141   SWEET !!...Don't bet against Mike C. and Dr. TTIME 04/24/18 06:03:28 PM
#28140   Good thing I bought some shares at $1.70 lakingsphan0427 04/24/18 06:00:06 PM
#28139   I've been picking up the cheapies under 2. SidVicious 04/24/18 05:53:16 PM
#28138   VERY GOOD NEWS AND WHY $MNKD IS UP SidVicious 04/24/18 05:50:01 PM
#28137   Did u buy any MNKD shares this week? $Pistol Pete$ 04/24/18 05:48:07 PM
#28136   No, but I saw that Mannkind gave its SidVicious 04/24/18 04:51:09 PM
#28135   Yep $Pistol Pete$ 04/24/18 04:30:39 PM
#28134   WTF...up 18% after market close Go4itbigtime 04/24/18 04:29:00 PM
#28133   Did u our see that golden cross yet? $Pistol Pete$ 04/24/18 04:28:48 PM
#28132   Nice close ;-) $Pistol Pete$ 04/24/18 04:00:18 PM
#28131   In human world? Unoqualunque 04/24/18 03:54:59 PM
#28130   This is a GREAT article on MNKD and SidVicious 04/24/18 01:24:41 PM
#28126   $MNKD Daily and Weekly Ichimoku Charts http:/ $Pistol Pete$ 04/24/18 02:18:52 AM
#28125   So you have no evidence of it is SidVicious 04/24/18 01:03:19 AM
#28124   I followed by the chart my Friend $Pistol Pete$ 04/23/18 11:28:14 PM
#28123   AWESOM, Stephen! That's the message so badly needed Scarbender307 04/23/18 11:06:19 PM
#28122   Riddle me this. Can you point to any SidVicious 04/23/18 10:38:36 PM
#28121   I first learned of MannKind though a friend WHS 04/23/18 09:59:16 PM
#28120   $MNKD looks like golden cross is coming for MNKD $Pistol Pete$ 04/23/18 09:02:14 PM
#28119   Because it was a holiday week. Don't worry. SidVicious 04/22/18 03:23:47 PM
#28118   Does anyone know why refills tracking down with pe2762 04/22/18 01:27:02 PM
#28117   It is not old data but key data terragord7 04/22/18 09:57:19 AM
#28116   Old data. We are two months from that SidVicious 04/22/18 09:50:17 AM
#28115   Well key metric up. Rise in institutional ownership terragord7 04/22/18 09:47:25 AM
#28113   Nope,under $2 is history soon imo TTIME 04/21/18 10:56:40 PM
#28112   Wrong yet again! SidVicious 04/20/18 04:55:46 PM
#28111   Thanks for continually reminding us just how bad SidVicious 04/20/18 09:50:24 AM
#28110   But it was a short week! SidVicious 04/20/18 09:41:52 AM
#28109   Looks like more Institutional buyers coming in interstate 04/20/18 07:14:01 AM
#28108   NEW SCRIPT NUMBERS -- read'em and weep IF parkourstar 04/20/18 03:45:56 AM
#28107   * * $MNKD Video Chart 04-19-18 * * ClayTrader 04/19/18 05:02:23 PM
#28106   Borrowing rates have come way down on MNKD. Hypi 04/19/18 01:44:56 PM